Reaction
Chronic Lymphocytic Leukaemia Recurrent reporting signals
As of the last recalculation, Chronic Lymphocytic Leukaemia Recurrent appears in 684 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is FLUDARABINE PHOSPHATE (PRR 280.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fludarabine Phosphate | 237 | 280.1 | 281.8 |
| Obinutuzumab | 83 | 174.6 | 175.5 |
| Rituximab | 429 | 164.0 | 164.3 |
| Venetoclax | 204 | 143.2 | 143.7 |
| Bendamustine Hcl | 59 | 126.6 | 127.1 |
| Acalabrutinib | 34 | 89.8 | 90.0 |
| Ibrutinib | 118 | 53.5 | 53.6 |
| Bendamustine Hydrochloride | 17 | 44.3 | 44.3 |
| Alemtuzumab | 22 | 35.7 | 35.8 |
| Cyclophosphamide Injection, Solution | 115 | 23.6 | 23.6 |
| Cyclophosphamide | 115 | 23.6 | 23.6 |
| Cyclophosphamide For Injection | 115 | 23.6 | 23.6 |
| Romiplostim | 8 | 16.3 | 16.4 |